DR. CATHERINE C. PARK, M.D.
Radiology at Divisadero St, San Francisco, CA
License number
California A72654
Category
Radiology
Type
Radiation Oncology
Address
Address
1600 Divisadero St, San Francisco, CA 94115
Phone
(415) 353-7175
(415) 353-9883 (Fax)
(415) 476-4029
(415) 476-4150 (Fax)
(415) 353-9883 (Fax)
(415) 476-4029
(415) 476-4150 (Fax)
Professional information
Product Manager
Position:
Product Manager at Xignite
Location:
San Francisco Bay Area
Industry:
Internet
Work:
Xignite
since 2012
-
Product Manager
UBP Asset Management
2008 - 2011
-
VP
UBP Asset Management
2006 - 2008
-
Associate
Highbridge Capital Management
2005 - 2005
-
Analyst (Contract)
Morgan Stanley Smith Barney
- Los Angeles, Ca 2003 - 2004
-
Intern, Wealth Management
Education:
University of California, Los Angeles 2001 - 2005
Catherine Chungihl Park, San Francisco CA
Specialties:
Radiology, Radiation Oncology, Family Medicine, Medical Oncology
Work:
Ucsf Radiation Oncology
1600 Divisadero St, San Francisco, CA 94115
1600 Divisadero St, San Francisco, CA 94115
Education:
University of California at Los Angeles (1995)
Professor At Ucsf
Position:
Professor at UCSF
Location:
San Francisco Bay Area
Industry:
Research
Work:
UCSF
-
Professor
Catherine C Park, San Francisco CA
Specialties:
Oncologist
Address:
1600 Divisadero St, San Francisco, CA 94115
505 Parnassus Ave, San Francisco, CA 94143
505 Parnassus Ave, San Francisco, CA 94143
Education:
UCLA, David Geffen School of Medicine - Doctor of Medicine
Board certifications:
American Board of Radiology Certification in Radiation Oncology (Radiology)
Method Of Increasing Radiation Sensitivity By Inhibition Of Beta One Integrin
US Patent:
2007023, Oct 11, 2007
Filed:
Jun 2, 2005
Appl. No.:
11/628476
Inventors:
Catherine Park - San Francisco CA, US
Mina Bissell - Berkeley CA, US
Mina Bissell - Berkeley CA, US
International Classification:
A61K 51/00, C07K 16/00, C07K 2/00, C12N 5/02
US Classification:
424001490, 435375000, 530300000, 530391300
Abstract:
A method for increasing or monitoring apoptosis in tumor cells by the co-administration of ionizing radiation and an anti-integrin antibody. Increasing apoptosis reduces tumor growth in vivo and in a cell culture model. The antibody is directed against the beta-1 integrin subunit and is inhibitory of beta-1 integrin signaling. Other molecules having an inhibitory effect on beta-1 integrin, either in signaling or in binding to its cognate extracellular receptors may also be used. The present method is particularly of interest in treatment of tumor cells associated with breast cancer, wherein radiation is currently used alone. The present method further contemplates a monoclonal antibody suitable for human administration that may further comprise a radioisotope attached thereto.
Method Of Increasing Radiation Sensitivity By Inhibition Of Beta One Integrin
US Patent:
8246952, Aug 21, 2012
Filed:
Oct 7, 2009
Appl. No.:
12/575411
Inventors:
Catherine Park - San Francisco CA, US
Mina J. Bissell - Berkeley CA, US
Mina J. Bissell - Berkeley CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 39/395
US Classification:
4241301
Abstract:
A method for increasing or monitoring apoptosis in tumor cells by the co-administration of ionizing radiation and an anti-integrin antibody. Increasing apoptosis reduces tumor growth in vivo and in a cell culture model. The antibody is directed against the beta-1 integrin subunit and is inhibitory of beta-1 integrin signaling. Other molecules having an inhibitory effect on beta-1 integrin, either in signaling or in binding to its cognate extracellular receptors may also be used. The present method is particularly of interest in treatment of tumor cells associated with breast cancer, wherein radiation is currently used alone. The present method further contemplates a monoclonal antibody suitable for human administration that may further comprise a radioisotope attached thereto.